Teva Pharmaceutical Industries Ltd (TEVA.N)
|Market Cap (Mil.):||$45,864.21|
|Shares Outstanding (Mil.):||948.43|
- Teva Pharmaceutical Industries Ltd agreed to pay $27.6 million to settle charges that it paid kickbacks to a Chicago psychiatrist to induce him to prescribe an anti-schizophrenia drug to patients, resulting in more than 100,000 false Medicaid and Medicare claims.
March 11 - Teva Pharmaceutical Industries Ltd agreed to pay $27.6 million to settle charges that it paid kickbacks to a Chicago psychiatrist to induce him to prescribe an anti-schizophrenia drug to patients, resulting in more than 100,000 false Medicaid and Medicare claims.
LONDON, Feb 21 - European regulators recommended the approval of a clutch of drugs to treat respiratory diseases on Friday, including two from GlaxoSmithKline and another from Teva Pharmaceuticals.
* Teva, Ranbaxy to pay $150,000 each to settle with New York State
Feb 18 - The New York Attorney General and the U.S. units of Ranbaxy Laboratories Ltd and Teva Pharmaceutical Industries Ltd have settled claims that an agreement between the two drugmakers unlawfully restricted competition.
Feb 18 - Generic drugmaker Actavis Plc said it would acquire specialty pharmaceuticals company Forest Laboratories Inc in a cash and stock deal valued at about $25 billion.
Feb 16 - Israeli drugmaker Teva Pharmaceutical Industries Ltd became the largest single stock holding for Soros Fund Management LLC, the family office of billionaire investor George Soros, in the fourth quarter, according to a Feb. 14 filing with the U.S. Securities and Exchange Commission.
Feb 10 - Teva Pharmaceutical Industries Ltd said on Monday that the U.S. Department of Justice has opened an investigation into the marketing and promotion of multiple sclerosis drug Copaxone and Parkinson's Disease treatment Azilect.
TEL AVIV - Teva Pharmaceutical Industries' fourth quarter earnings rose 8 percent, beating analysts' estimates, on stronger sales from specialty medicines and U.S. generic drugs.
TEL AVIV, Feb 6 - Teva Pharmaceutical Industries' fourth quarter earnings rose 8 percent, beating analysts' estimates, on stronger sales from specialty medicines and U.S. generic drugs.
Earnings vs. Estimates
Analyst Research Reports
Validea Guru Analysis Report for TEVA. Analysis using Validea's interpretation of the published quantitative strategies of well-known Wall Street experts including Peter Lynch, Warren Buffett, Ben Graham and Ken Fisher, among others.
Trading Report for (TEVA). A detailed report, including free correlated market analysis, and updates.
Provider: Stock Traders Daily
Provider: New Constructs, LLC
Jefferson Research Financial Sonar Report. A detailed analysis of the current fundamental performance of TEVA PHARMACEUTICAL INDS-ADR including Earnings Quality, Cash Flow Quality, Operating Efficiency, Balance Sheet Quality and Valuation.
Provider: Jefferson Research
Provider: ValuEngine, Inc.